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Objectives We examined the hemodynamic, echocardiographic, and neurohormonal effects of intravenous istaroxime in
patients hospitalized with heart failure (HF).
Background Istaroxime is a novel intravenous agent with inotropic and lusitropic properties related to inhibition of Na/K
adenosine triphosphatase (ATPase) and stimulation of sarcoplasmic reticulum calcium ATPase.
Methods One hundred twenty patients admitted with HF and reduced systolic function were instrumented with a pulmo-
nary artery catheter within 48 h of admission. Three sequential cohorts of 40 patients each were randomized
3:1 istaroxime:placebo to a continuous 6-h infusion. The first cohort received 0.5 g/kg/min, the second 1.0
g/kg/min, and the third 1.5 g/kg/min istaroxime or placebo.
Results All doses of istaroxime lowered pulmonary capillary wedge pressure (PCWP), the primary end point (mean  SD:
3.2  6.8 mm Hg, 3.3  5.5 mm Hg, and 4.7  5.9 mm Hg compared with 0.0  3.6 mm Hg with pla-
cebo; p  0.05 for all doses). Istaroxime significantly decreased heart rate (HR) and increased systolic blood
pressure (SBP). Cardiac index increased and left ventricular end-diastolic volume decreased significantly only
with 1.5 g/kg/min. On echocardiography, left ventricular end diastolic volume and deceleration time improved
with 1.5 g/kg/min. There were no changes in neurohormones, renal function, or troponin I. Adverse events
were not life threatening and were dose related.
Conclusions In patients hospitalized with HF, istaroxime improved PCWP and possibly diastolic function. In contrast to avail-
able inotropes, istaroxime increased SBP and decreased HR. (A Phase II Trial to Assess Hemodynamic Effects of
Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function [HORIZON-HF]; NCT00616161) (J Am
Coll Cardiol 2008;51:2276–85) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.015r
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wospitalizations for acute heart failure syndromes (AHFS)
ontinue to increase, and are associated with high post-
ischarge mortality and hospitalizations (1). The main
rom the *Feinberg School of Medicine, Northwestern University, Chicago, Illinois;
University Hospital Attikon, Athens, Greece; ‡National Institute of Cardiovascular
isorders, Bucharest, Romania; §National Institute of Cardiology, Warsaw, Poland;
CC Iliescu Heart Diseases Institute, Bucharest, Romania; Sigma-Tau, Pomezia
Rome), Italy; and the #Department of Medicine, Henry Ford Hospital, Detroit,
ichigan. Supported by Sigma-Tau i.f.r., SpA.m
Manuscript received February 28, 2008; revised manuscript received March 21,
008, accepted March 21, 2008.eason for admissions is related to congestion (2). Although
ost patients are normotensive or hypertensive on admis-
ion, approximately 10% present with a low cardiac output
3). For this group, existing guidelines recommend intra-
See page 2286
enous inotropes (4,5). Although available inotropes
mprove hemodynamics, their use has been associated
ith hypotension arrhythmias and possibly increased
ortality (6 – 8).
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June 10, 2008:2276–85 Istaroxime in Acute HFIstaroxime is a novel intravenous agent that inhibits sodium-
otassium adenosine triphosphatase (ATPase) activity while
timulating sarcoplasmic reticulum calcium ATPase isoform 2.
he combined mechanism of istaroxime allows for cytosolic
alcium accumulation during systole (inotropic response), as
ell as rapid sequestration of calcium during diastole and
yocardial relaxation (lusitropic response) (9,10). In the ani-
al model, istaroxime improves systolic and diastolic function
ithout increasing myocardial oxygen consumption (11,12). In
hronic heart failure (HF), istaroxime is relatively safe in doses
p to 5 g/kg/min (13).
The objective of the present study was to determine the
hort-term effects of 3 different doses of istaroxime in
atients with AHFS.
ethods
he HORIZON-HF (Hemodynamic, Echocardiographic,
nd Neurohormonal Effects of Istaroxime, a Novel Intrave-
ous Inotropic and Lusitropic Agent: a Randomized Con-
rolled Trial in Patients Hospitalized with Heart Failure)
tudy was conducted in Poland, Romania, and Greece. The
tudy protocol was approved by site-specific independent
nstitutional ethics committees and conducted according to
he amended Declaration of Helsinki. All patients provided
nformed written consent. An independent data and safety
onitoring board had access to unblinded data for evalua-
ion of safety results.
atients. The study included patients age 18 to 85 years
ith a left ventricular ejection fraction (LVEF) 35%,
ospitalized with HF with a systolic blood pressure (SBP)
150 and 90 mm Hg, heart rate (HR) 110 and 60
120 Patie
29 Randomized to Istaroxime 0.5 µg/kg/min
11 Randomized to Placebo*
30 Randomized to 
10 Randomized to 
30 Randomized to 
Istaroxime 1.0 µg/kg/min
29 Randomized to 
Istaroxime 0.5 µg/kg/min
0 Did Not Complete 
Study
0 Did Not Complete        
Treatment Infusion    
Period
2 Did Not Complete 
Study 
0 Did Not Complete 
Treatment Infusion 
Period
29 Included in Efficacy  
Analysis
29 Included in Safety   
Analysis
144 with P
Cathete
30 Included in Efficacy  
Analysis
30 Included in Safety   
Analysis
Figure 1 Enrollment
The imbalance in number of patients (29 instead of 30 in the 0.5 g/kg/min gro
error. INR  International Normalized Ratio for Prothrombin Time; PCWP  pulmoneats/min, and on standard HF
herapy. The main exclusion cri-
eria were use of intravenous ino-
ropes, serum digoxin concentra-
ion 0.5 ng/ml, recent acute
oronary syndromes or coronary
evascularization, atrial fibrilla-
ion, left bundle branch block,
mplanted electrical devices, se-
um creatinine levels above 3.0
g/dl, and severe liver enzyme
bnormalities.
tudy plan. This was a random-
zed, double-blind, placebo-
ontrolled, dose-escalation study.
fter informed consent, patients
ere instrumented with a contin-
ous cardiac output pulmonary ar-
ery catheter (PAC) within 48 h of
dmission and observed for 6 h,
fter which time a pulmonary cap-
llary wedge pressure (PCWP)
20 mm Hg was required. This was followed by 2 h during
hich time PCWP variability was 10% on 3 consecutive
eterminations.
Patients were centrally randomized to istaroxime or
lacebo at a ratio of 3:1 within 3 sequential cohorts of 40
atients each. The first cohort was randomized to 0.5
g/kg/min, the second cohort to 1.0 g/kg/min, and the
hird to 1.5 g/kg/min of istaroxime or placebo. Study
edication was administered intravenously at a rate of
omized
e 1.0 µg/kg/min 30 Randomized to Istaroxime 1.5 µg/kg/min
10 Randomized to Placebo
31 Randomized to Placebo0 Randomized to 
taroxime 1.5 µg/kg/min
0 Did Not Complete 
Study 
1 Did Not Complete 
Treatment Infusion 
Period due to 
Adverse Event
0 Did Not Complete 
Study 
1 Did Not Complete 
Treatment Infusion 
Period due to
Adverse Event
y Artery 
laced
24 Excluded:
15 PCWP ≤ 20 mmHg
3 Withdrawal consent
2 Technical problem with PAC
2 Serum digoxin >0.5 ng/mL
1 INR >1.2
1 Enrolled after randomization period
30 Included in Efficacy  
Analysis
30 Included in Safety   
Analysis
31 Included in Efficacy  
Analysis
31 Included in Safety   
Analysis
due to an assignment
pillary wedge pressure.
Abbreviations
and Acronyms
AHFS  acute heart failure
syndromes
CAD  coronary artery
disease
CI  cardiac index
DBP  diastolic blood
pressure
HF  heart failure
HR  heart rate
LV  left ventricular
LVEF  left ventricular
ejection fraction
PAC  pulmonary artery
catheter
PCWP  pulmonary
capillary wedge pressure
SBP  systolic blood
pressurents Rand
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Istaroxime in Acute HF June 10, 2008:2276–8500 ml/h for 6 h. Escalation to the next dose occurred
fter completion of the previous cohort as determined by
he data and safety monitoring board. After insertion of
he PAC until 2 h after infusion, no patients received new
F medications or intravenous inotropes or vasodilators.
tudy end points. The primary end point was change in
CWP compared with placebo after a 6-h continuous
nfusion. Secondary end points included changes in cardiac
ndex (CI), right atrial pressure, SBP, diastolic blood pres-
ure (DBP), HR, and stroke work index. In addition,
hanges in LVEF, left ventricular (LV) end-diastolic and
systolic volumes, diastolic function indexes, neurohor-
ones, renal function, troponin, pharmacokinetics, and
afety were evaluated.
emodynamics. Hemodynamic variables were measured
y PAC 8 h before, during, and 2 h after infusion. The CI
as continuously measured with a Vigilance II monitor
Edwards Lifesciences, Irvine, California). The PCWP was
Baseline Clinical Features
Table 1 Baseline Clinical Features
Is
0.5 (n  29)
Demographics
Age, mean (SD), yrs 54 (11)
Male, n (%) 26 (90)
Caucasian, % 100
Weight, mean (SD), kg 81 (13)
Height, mean (SD), cm 172 (9)
Physical findings and symptoms
SBP, mean (SD), mm Hg 115 (10)
DBP, mean (SD), mm Hg 69 (8)
HR, mean (SD), beats/min 75 (10)
Jugular venous distension, n (%) 24 (83)
Rales, n (%) 18 (62)
Edema, n (%) 14 (48)
NYHA functional class, n (%)
II 9 (31)
III 18 (62)
IV 2 (7)
Etiology of HF
CAD, n (%) 17 (59)
Idiopathic, n (%) 10 (34)
Other, n (%) 2 (7)
Medical history
Myocardial infarction, n (%) 14 (48)
CABG, n (%) 1 (3)
PCI, n (%) 8 (28)
Diabetes mellitus, n (%) 9 (31)
Medications before infusion
Diuretic, n (%) 28 (96)
ACE, n (%) 29 (100)
ARB, n (%) 2 (7)
Beta-blocker, n (%) 29 (100)
Spironolactone, n (%) 20 (69)
Digoxin, n (%) 3 (10)
ACE angiotensin-converting enzyme; ARB angiotensin receptor blo
DBP  diastolic blood pressure; HR  heart rate; NYHA  New York Heart As
blood pressure.btained at end-expiration. The SBP, DBP, and HR were
easured noninvasively. The pulmonary vascular resistance,
ystemic vascular resistance, and stroke work index were
alculated using standard formulas. Study personnel had to
ass all tests in the learning module of the Pulmonary
rtery Catheter Education Project. All tracings were cen-
rally reviewed.
chocardiography. Echocardiography was performed be-
ore and within the last 30 min of infusion. Ventricular
olumes were measured using the biplane method of
iscs, with LVEF calculated using the standard formula.
itral regurgitation was observer graded on a scale of 0
o 3 (none, mild, moderate, and severe). Mitral inflow
elocities were measured by pulsed-wave Doppler in the
pical 4-chamber view. Peak velocity of the early and late
iastolic mitral inflow (E and A waves), and the E-wave
eceleration time were recorded. Tissue Doppler mea-
urements were obtained using real-time pulsed-wave
e (g/kg/min)
0 (n  30) 1.5 (n  30) Placebo (n  31)
56 (11) 54 (11) 57 (10)
26 (87) 28 (93) 25 (81)
100 100 100
83 (14) 79 (14) 81 (13)
171 (8) 171 (8) 172 (8)
118 (9) 117 (15) 113 (15)
71 (6) 70 (8) 70 (8)
73 (8) 73 (9) 72 (11)
24 (80) 24 (80) 26 (84)
22 (73) 18 (60) 14 (45)
10 (33) 8 (27) 12 (39)
13 (43) 10 (33) 12 (39)
15 (50) 19 (63) 18 (58)
2 (7) 1 (3) 1 (3)
18 (60) 21 (70) 21 (68)
12 (40) 9 (30) 9 (29)
0 (0) 0 (0) 1 (3)
12 (40) 12 (40) 13 (42)
1 (3) 2 (7) 4 (13)
6 (20) 6 (20) 10 (32)
3 (10) 4 (13) 5 (16)
28 (93) 22 (73) 30 (97)
26 (87) 27 (97) 26 (84)
3 (7) 4 (13) 3 (10)
28 (93) 30 (100) 31 (100)
18 (60) 17 (57) 25 (81)
0 (0) 2 (7) 4 (13)
BG coronary artery bypass grafting; CAD coronary artery disease;taroxim
1.
cker; CA
sociation; PCI  percutaneous coronary intervention; SBP  systolic
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June 10, 2008:2276–85 Istaroxime in Acute HFoppler. Peak systolic and early diastolic velocities (Ea
nd Sa) were measured.
eurohormones, renal function, and cardiac troponin.
-type natriuretic peptide, plasma renin activity, aldoste-
one, blood urea nitrogen, creatinine, serum sodium, and
roponin I were measured before and after the infusion.
ll blood samples were analyzed by a core laboratory.
harmacokinetics. Blood samples were withdrawn be-
ore, during, and up to 18 h after starting infusion for
harmacokinetics. Analyses were calculated using the
alidated software Kinetica version 4.4 (Thermo Electron
orp., Waltham, Massachusetts).
afety. Urinalysis, hematology, serum chemistry, and contin-
ous 12-lead Holter monitoring were performed. Adverse
vents were monitored in the hospital during and 24 h after the
eginning of infusion and telephonically at 7 and 30 days.
tatistical analysis. All randomized patients were included
n the statistical analysis, according to the intention-to-treat
rinciple. Patients included in the efficacy analysis under-
ent at least baseline and 1 post-baseline assessment in
ccordance with the last observation carried forward
ethod. Safety analyses were carried out on all patients who
Baseline Hemodynamic, Echocardiographic, and
Table 2 Baseline Hemodynamic, Echocardio
I
0.5 (n  29)
Baseline hemodynamics
PCWP, mm Hg 26.2 (6.2)
CI, l/min/m2 2.7 (0.9)
RAP, mm Hg 12.9 (4.1)
Baseline echocardiography
LVEF, % 26.8 (7.3)
LVESV, ml 161.3 (62.9)
LVEDV, ml 213.7 (65.6)
MR, grade 1.7 (0.8)
Sa, cm/s 5.4 (2.1)
E peak, cm/s 79 (27)
A peak, m/s 50 (22)
E/A ratio 2.0 (1.3)
Deceleration time, ms 146 (60)
Ea, cm/s 6.9 (2.9)
E/Ea ratio 16 (13)
Neurohormones, renal function,
cardiac troponin and
electrophysiology
BNP, pg/ml* 328 (875.0)
PRA, ng/ml/h* 3.7 (6.9)
Aldosterone, pg/ml* 94.0 (257.0)
Na, mmol/l 136.9 (15.7)
BUN, mg/dl 25.7 (36.5)
Cr, mg/dl 1.07 (0.44)
TnI, ng/ml 0.24 (0.14)
QTc, ms 445.9 (27.5)
Data reported as mean (SD) or *median (interquartile range).
A peak peak A-wave velocity; BNP B-type natriuretic peptide; BUvolume; MR  mitral regurgitation; PCWP  pulmonary capillary wedge pres
Sa  systolic mitral annular velocity; TnI  troponin I.tarted study treatment infusion. Data are summarized as
ean  SD.
Sample size estimate was based on the primary end point,
CWP. Assuming   0.05 and   0.20 (corresponding
o a power of 80%) and conducting a 2-tailed t test, using a
ommon SD observed from previous studies of 6 mm Hg, a
otal of 24 patients per group was required to detect a
reatment difference in PCWP of 5 mm Hg. Taking into
ccount a higher variability of PCWP, an additional 20% of
atients was added.
Two separate analyses were performed on all hemody-
amic parameters. The analysis of variance model, with a
ingle effect for treatment, was used for analyzing the
hanges from baseline to 6 h of infusion. An analysis of
ariance model for repeated measurements, including
erms for treatment, time, and treatment–time interac-
ion, was used to analyze trends during the 6 h of
nfusion. A step-down testing procedure to account for
he multiple comparisons between the 3 doses of istar-
xime versus placebo was used to interpret the results of
ll statistical tests. Therefore, the comparisons were
onsidered in a predefined order, beginning with com-
ratory Variables
ic, and Laboratory Variables
ime (g/kg/min)
.0 (n  30) 1.5 (n  30)
Placebo
(n  31)
25.1 (5.7) 26.7 (6.2) 25.0 (4.6)
2.90 (0.8) 2.7 (0.9) 2.6 (0.6)
12.5 (3.7) 13.4 (3.6) 14.3 (3.5)
27.5 (6.1) 28.6 (6.4) 26.1 (6.5)
67.7 (59.6) 140.7 (45.7) 142.0 (38.2)
09.8 (71.8) 196.7 (53.9) 190.8 (51.1)
1.5 (0.8) 1.1 (0.8) 1.4 (0.8)
7.1 (4.1) 6.4 (2.9) 6.8 (3.3)
74 (18) 79 (29) 74 (25)
58 (21) 58 (32) 53 (26)
1.5 (1.0) 2.1 (1.6) 1.9 (1.3)
162 (47) 155 (64) 165 (67)
9.6 (3.8) 7.5 (2.8) 8.5 (4.4)
10 (6) 13 (9) 11 (6)
171 (404.5) 201 (529.0) 207 (586.0)
2.0 (4.7) 2.7 (6.4) 0.8 (5.9)
92.5 (154.5) 84.0 (159.0) 54.0 (51.0)
27.2 (24.0) 129.7 (17.6) 124.4 (22.8)
20.3 (14.1) 18.6 (6.3) 23.5 (26.8)
1.05 (0.24) 1.02 (0.18) 1.00 (0.19)
0.23 (0.12) 0.22 (0.09) 0.19 (0.04)
45.3 (25.6) 448.6 (30.1) 447.1 (34.3)
od urea nitrogen; CI cardiac index; Cr creatinine; Ea early mitralLabo
graph
starox
1
1
2
1
4
N blo
annular velocity; E peak peak E-wave velocity; LVEDV LV end-diastolic volume; LVEF left ventricular ejection fraction; LVESV LV end-systolicsure; PRA  plasma renin activity; RAP  mean right atrial pressure;
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Figure 2 Invasive Hemodynamics Over the Course of Infusion
Pulmonary capillary wedge pressure (PCWP), cardiac index (CI), mean right atrial pressure (RAP), and stroke work index (SWI), plotted over the time course of treatment
with placebo (purple) or istaroxime 0.5 g/kg/min (blue), 1.0 g/kg/min (red), and 1.5 g/kg/min (green). The p values refer to the main effect, by repeated-
measures analysis.-3
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Figure 3 Noninvasive Hemodynamic Parameters Over the Course of Infusion
Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and heart rate (HR), plotted over the time course of treatment with placebo
(purple) or istaroxime 0.5 g/kg/min (blue), 1.0 g/kg/min (red), and 1.5 g/kg/min (green). The p values refer to the main effect, by repeated-measures analysis.
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June 10, 2008:2276–85 Istaroxime in Acute HFarison of the highest dose of istaroxime versus placebo
nd taking into account the next dose only if the previous
omparison was statistically significant at the 0.05 level.
ll statistical analyses were performed using SAS soft-
are, version 8.2 (SAS Institute, Cary, North Carolina).
esults
etween August 7, 2006, and July 5, 2007, 120 patients
ere randomized to receive placebo or istaroxime over 6 h,
ut of a total of 144 patients who consented to treatment
nd were instrumented with a PAC (Fig. 1).
aseline characteristics. Of the 120 randomized patients,
05 were men and 15 were women, with a mean age of 55
Mean 95% Confidence In
PCWP (mmHg)
0.50 µg/kg/min -3.2 -5.8 -0.6
1.00 µg/kg/min -3.3 -5.4 -1.3
1.50 µg/kg/min -4.7 -6.9 -2.5
Placebo 0.0 -1.3 1.3
CI (L/min/m2)
0.50 µg/kg/min -0.04 -0.3 0.3
1.00 µg/kg/min 0.1 -0.1 0.4
1.50 µg/kg/min 0.3 -0.04 0.6
Placebo -0.01 -0.3 0.2
Mean RAP (mmHg)
0.50 µg/kg/min -1.1 -2.4 0.1
1.00 µg/kg/min -1.1 -1.8 -0.3
1.50 µg/kg/min -1.5 -3.1 0.1
Placebo -0.3 -1.1 0.5
SWI (g-m/m2/beat)
0.50 µg/kg/min 2.7 -1.5 6.9
1.00 µg/kg/min 6.2 2.1 10.4
1.50 µg/kg/min 9.8 3.8 15.8
Placebo 1.8 -1.7 5.3
SBP (mmHg)
0.50 µg/kg/min 4.9 1.0 8.8
1.00 µg/kg/min 8.3 3.8 12.8
1.50 µg/kg/min 15.6 9.8 21.5
Placebo 1.3 -2.8 5.5
DBP (mmHg)
0.50 µg/kg/min 0.9 -3.2 4.9
1.00 µg/kg/min 0.8 -2.7 4.3
1.50 µg/kg/min 3.4 -0.2 7.0
Placebo 0.6 -2.0 3.2
MAP (mmHg)
0.50 µg/kg/min 2.2 -1.3 5.7
1.00 µg/kg/min 3.3 -0.1 6.6
1.50 µg/kg/min 7.5 3.8 11.2
Placebo 0.9 -1.8 3.6
HR (beats/min)
0.50 µg/kg/min -1.8 -5.5 1.9
1.00 µg/kg/min -2.6 -6.1 0.9
1.50 µg/kg/min -1.1 -6.2 4.0
Placebo 0.3 -1.9 2.4
-6 -3
Cha
Figure 4 Hemodynamics After Infusion
The p values refer to the comparison of each dose versus placebo. Abbreviations 11 years (Table 1). Before infusion, patients were meceiving standard HF therapy (Table 1). The mean SBP
as 116  13 mm Hg, DBP 70  8 mm Hg, HR 73  10
eats/min, PCWP 25  5 mm Hg, CI 2.7  0.8 l/min/m2,
VEF 27  7%, and B-type natriuretic peptide 433  524
g/ml (Table 2).
rimary end point. A reduction in PCWP was observed
ith all 3 doses of istaroxime at the first measured time
oint (0.5 h) as well as at 6 h compared with placebo (Fig.
). The mean change in PCWP at 6 h was 3.2  6.8
m Hg, 3.3  5.5 mm Hg, and 4.7  5.9 mm Hg,
or the 0.5, 1.0, and 1.5 g/kg/min istaroxime infusions,
espectively, compared with 0.0  3.6 mm Hg for
lacebo (p  0.05 for all doses of istaroxime vs. placebo).
econdary end points. HEMODYNAMICS. Changes in he-
l
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Istaroxime in Acute HF June 10, 2008:2276–85fter 6-h infusion are shown in Figure 4. During infusion,
n increase was seen in SBP in the 1.0 and 1.5 g/kg/min
roups (p  0.005 and  0.001, respectively) compared
ith placebo; this pattern was consistent with the one
bserved at the end of the 6-h infusion (8.3  12.1 mm
g and 15.6  15.3 mm Hg [p  0.02 and  0.001,
espectively] vs. 1.3  11.3 mm Hg for the placebo
roup). No significant changes were noted in DBP. The
R decreased in a dose-dependent manner during istar-
xime infusion (p  0.008, 0.02, and 0.006, with 0.5, 1.0
nd 1.5 g/kg/min, respectively) compared with placebo,
ut did not achieve statistical significance at the 6-h time
oint. The CI increased during the 1.5 g/kg/min infusion
ersus placebo in repeated-measures analysis (p  0.04 vs.
lacebo), but not at the end of the 6-h infusion. There were
o significant changes in systemic or pulmonary vascular
esistance
CHOCARDIOGRAPHY. The LV end-systolic volume was
educed in the 1.0 g/kg/min istaroxime group compared
ith placebo (15.8  22.7 ml vs. 2.1  25.5 ml; p 
.03), and LV end-diastolic volume was reduced in the
.5 g/kg/min group compared with placebo (14.1 
6.3 ml vs. 3.9  32.4 ml; p  0.02). There were no
ignificant increases in LVEF in the istaroxime groups
Fig. 5). The Sa velocity increased in the 0.5 and 1.5
g/kg/min groups (1.0  1.3 cm/s and 1.4  1.6 cm/s;
 0.001 for both doses) compared with 0.3  1.1
m/s with placebo (Table 3). E-wave deceleration time
ncreased in the 1.5 g/kg/min group (30  51 ms vs.
3  51 ms; p  0.04), and Ea velocity increased in the
.5 and 1.5 g/kg/min groups (0.9  2.9 cm/s and
0.6  2.4 cm/s, respectively) compared with placebo
Mean 95% Confiden
LVEF (%)
0.50 µg/kg/min 2.6 1.3 3.9
1.00 µg/kg/min 3.5 2.0 4.9
1.50 µg/kg/min 3.9 2.4 5.4
Placebo 2.8 1.5 4.1
LVESV (ml)
0.50 µg/kg/min -5.9 -11.4 -0.4
1.00 µg/kg/min -15.8 -24.2 -7.3
1.50 µg/kg/min -5.7 -15.7 4.2
Placebo -2.1 -11.8 7.6
LVEDV (ml)
0.50 µg/kg/min 2.9 -5.9 11.7
1.00 µg/kg/min -6.4 -16.1 3.3
1.50 µg/kg/min -14.1 -24.0 -4.3
Placebo 3.9 -8.4 16.2
-25
Figure 5 Left Ventricular Volumes After Infusion
The p values refer to the comparison of each dose versus placebo. LVEDV  left v
end-diastolic volume; LVEF  left ventricular ejection fraction; LVESV  left ventric0.7  2.5 cm/s; p  0.06 for both comparisons). There
as a small decrease in the E/Ea ratio in the 0.5 g/kg/min
roup compared with placebo (3.8  9.6 vs. 1.2  4.2,
 0.03). There was no significant change in E- or A-wave
elocities or their ratio in any of the istaroxime groups
ompared with placebo.
EUROHORMONES, RENAL FUNCTION, CARDIAC TROPO-
IN, AND ELECTROCARDIOGRAPHY. There were no signif-
cant changes in neurohormones, blood urea nitrogen,
reatinine, or troponin I (Table 4). Serum sodium decreased
n all groups and attained statistical significance in the 0.5
g/kg/min group. There was significant shortening of the
Tc interval with all doses of istaroxime compared with
lacebo.
HARMACOKINETICS. Istaroxime has a half-life of less than
h. During the infusion, plasma istaroxime increased
apidly at first, and then gradually, reaching a steady state at
to 5 h. The short half-life may be due to the high systemic
learance (3.5 to 3.9 l/kg) despite a large volume of
istribution (2 l/kg). Istaroxime does not appear to be
xcreted by the kidney and is converted into 3 metabolites
hat are less active than istaroxime.
DVERSE EVENTS. No deaths occurred during the treat-
ent period. Two patients died within 30 days of random-
zation: one due to worsened HF and the other due to
udden cardiac death (Table 5). Premature discontinuation
f the infusion occurred in 1 patient in the 1.5 g/kg/min
roup owing to treatment with a medication not allowed,
nd in 1 patient in the placebo group owing to clinical
orsening. The main side effects were vomiting and pain at
he infusion site.
erval
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he administration of intravenous istaroxime, a novel ino-
ropic agent with lusitropic properties, when added to
tandard therapy, resulted in a rapid improvement in
CWP in patients hospitalized with HF and reduced
VEF. This was associated with an increase in SBP and
ecrease in HR and LV end-diastolic volume. The CI and
troke work index were improved only with the highest dose
ested.
Doppler and tissue Doppler measurements demonstrated
mprovement in E-wave deceleration time, a marker of
V stiffness, as well as Ea and Sa velocities. Istaroxime
as associated with reductions in QTc interval, indepen-
ent of dose.
The majority of patients admitted with AHFS have
ulmonary and systemic congestion related to high LV
lling pressures rather than low cardiac output as the main
ause for hospitalization (2). Although most are normo-
ensive or hypertensive on admission, approximately 10%
resent with low blood pressure as a result of low cardiac
utput (3,6,7). Existing guidelines recommend inotropic
gents for the management of such patients (4,5). These agents
re known to improve hemodynamics, but their use is often
ssociated with hypotension and arrhythmias (6–8).
oppler and Tissue Doppler Echocardiography After Infusion
Table 3 Doppler and Tissue Doppler Echocardiography After Inf
Istaroxim
0.5 (n  29) 1.0
Mean Change (SD) p Value Mean Chang
MR, grade 0 (0.3) 0.6 0.1 (0.
Sa, cm/s* 1.0 (1.3) 0.001 0.6 (3.
E peak, cm/s 3 (13) 0.9 8 (15
A peak, cm/s 3 (16) 0.9 7 (16
E/A ratio 0.3 (0.7) 1 0.4 (0.
Deceleration time, ms 5 (32) 0.8 24 (63
Ea, cm/s* 0.9 (2.9) 0.06 0.1 (2.
E/Ea ratio† 3.8 (9.6) 0.03 1.1 (4.
n  20, 27, 30, and 26 for 0.5, 1.0, and 1.5 g/kg/min istaroxime and placebo, respectively. †
Abbreviations as in Table 2.
eurohormones, Renal Function, Cardiac Troponin, and Electrophys
Table 4 Neurohormones, Renal Function, Cardiac Troponin, and
Istaroxim
0.5 (n  29) 1.0
Mean Change (SD) p Value Mean Change
BNP, pg/ml* 0 (189.0) 0.8 16.0 (73.
PRA, ng/ml/h* 0.93 (3.13) 0.3 0.725 (2.3
Aldosterone, pg/ml* 42.0 (234.5) 0.2 30.5 (96.
Na, mmol/l 3.7 (10.0) 0.006 -4.1 (21.
BUN, mg/dl 0.4 (1.9) 0.5 0.9 (3.0
Cr, mg/dl 0.07 (0.40) 0.3 0.002 (0.0
TnI, ng/ml 0.02 (0.17) 0.3 0.00 (0.1
QTc, ms 25.7 (22.2) 0.0001 38.0 (17.Data reported as median (interquartile range).
Abbreviations as in Table 2.In the REVIVE (Randomized Evaluation of Intravenous
evosimendan Efficacy) I and II trials, the short-term
nfusion of levosimendan resulted in a modest clinical
mprovement, but was associated with hypotension, atrial
nd ventricular arrhythmias, and a trend toward an increase
n early mortality (14).
The SURVIVE (Survival of Patients With Acute Heart
ailure in Need of Intravenous Inotropic Support) trial
ompared the effects of short-term infusion of levosimendan
ith dobutamine in patients admitted with severe HF (15).
oth drugs led to severe hypotension in approximately 15%
f patients.
The short-term use of intravenous inotropes with
asodilatory properties has been have been associated
ith an increase in post-discharge mortality (6,7). It is
ossible that this post-infusion effect is related to myo-
ardial injury occurring during the short-term infusion
16). In the ischemic swine model, dobutamine given for
short period of time results in necrosis of hibernating
yocardium (17). Available data suggest that troponin
elease is relatively common in patients admitted with
HFS who have CAD (18). In a retrospective analysis of
he OPTIME-CHF (Outcomes of a Prospective Trial of
ntravenous Milrinone for Exacerbations of Chronic
/kg/min)
30) 1.5 (n  30) Placebo (n  29)
p Value Mean Change (SD) p Value Mean Change (SD)
0.6 0.3 (0.4) 0.3 0.05 (0.4)
0.2 1.4 (1.6) 0.001 0.3 (1.1)
0.1 1 (18) 0.3 3 (11)
0.3 10 (16) 0.1 3 (16)
0.5 0.6 (1.1) 0.2 0.3 (0.9)
0.2 30 (51) 0.04 3 (51)
0.3 0.6 (2.4) 0.06 0.7 (2.5)
0.06 0.4 (9.2) 0.4 1.2 (4.2)
, 27, 30, and 16 for 0.5, 1.0, and 1.5 g/kg/min istaroxime and placebo, respectively.
y With Istaroxime at 6 h
trophysiology With Istaroxime at 6 h
kg/min)
30) 1.5 (n  30) Placebo (n  31)
p Value Mean Change (SD) p Value Mean Change (SD)
0.3 14.5 (165.0) 0.3 1.0 (77.0)
0.2 0.61 (3.45) 0.4 0.47 (2.1)
0.7 9.0 (139) 0.5 18.0 (54.0)
0.08 2.2 (7.5) 0.5 3.7 (10.4)
0.9 0.7 (2.4) 0.9 0.8 (2.8)
0.5 0.091 (0.354) 0.2 0.011 (0.051)
0.5 0.21 (1.17) 0.4 0.02 (0.08)
0.0001 49.2 (30.3) 0.0001 2.4 (17.0)usion
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Istaroxime in Acute HF June 10, 2008:2276–85eart Failure) study, the addition of short-term infusion
f milrinone to standard therapy in patients with AHFS
nd CAD was associated with a 30% increase in post-
ischarge mortality (19). It is hypothesized that further
ecreases in blood pressure in patients with AHFS, as is
een with the available inotropic agents, may reduce coro-
ary perfusion and thus result in injury, particularly in
atients with CAD and ischemic or hibernating myocar-
ium (16).
Although other inotropes improve cardiac performance
o a similar or greater extent than istaroxime, the main
ifference with this agent is the effect of blood pressure and
ossibly HR and diastolic function.
tudy limitations. We did not study the effects of istar-
xime on symptoms. Patients who required inotropic sup-
ort were excluded. However, it is not feasible to randomize
Adverse Events
Table 5 Adverse Events
Is
0.5 (n  29)
Events during infusion
Bradycardia 0
Tachycardia 0
Ventricular extrasystoles 0
Ventricular tachycardia 0
QT prolonged 0
Left bundle branch block 0
Electrocardiogram ST-T change 0
Angina 0
Chest pain 0
Dyspnea 0
Acute pulmonary edema 0
Nausea 1 (1)
Vomiting 1 (1)
Abdominal pain 0
Malaise 0
Injection site pain, irritation,
inflammation, or pruritis
1 (1)
Catheter site pain 0
Extremity pain 1 (1)
Events within 30 days after infusion
Sudden cardiac death 0
Heart failure 0
Angina pectoris 1 (1)
Atrial fibrillation 0
Conduction disorders 0
Ventricular extrasystoles 1 (1)
Ventricular fibrillation 1 (1)
Ischemic stroke 1 (1)
Transient ischemic attack 0
Left bundle branch block 0
Back pain 0
Arthralgia 0
Extremity pain 0
Leg ischemia 1 (1)
Values are no. of patients (no. of events). *Occurred in the same patieatients with AHFS who require inotropes to placebo. iardiac output was higher than that of other studies in
HFS. There was no core lab analysis of echocardiogra-
hy, and therefore the results should be interpreted with
aution. Patient enrollment occurred in 3 sequential
locks. In such a design the dose effect could be con-
ounded with the period effect generated by changes in
xperimental conditions over time.
onclusions
staroxime, with its dual inotropic and lusitropic properties,
hows promise in the management of AHFS, given its
ffects on PCWP, HR, SBP and possibly diastolic function.
owever, the fate of istaroxime will depend on its effects on
n-hospital and post-discharge clinical outcomes, especially
me (g/kg/min)
.0 (n  30) 1.5 (n  30) Placebo (n  31)
0 2 (2) 0
0 1 (1)* 1 (1)
1 (1) 0 0
2 (3) 0 0
2 (2) 0 0
1 (1) 0 0
0 1 (1)* 0
0 1 (2)* 0
0 1 (1) 1 (1)
0 1 (1) 0
0 0 1 (1)
1 (1) 3 (5) 0
1 (1) 5 (12) 0
1 (1) 0 1 (1)
0 1 (1) 0
1 (1) 9 (9) 0
0 1 (1) 1 (1)
1 (1) 3 (3) 0
1 (1)† 0 0
1 (1)† 2 (2) 0
0 0 0
0 1 (1) 0
1 (1) 0 0
0 0 0
0 0 0
0 0 0
1 (1) 0 0
0 0 1 (1)
1 (1) 0 0
0 0 1 (1)
0 0 1 (1)
0 0 0
eath.taroxi
1n patients presenting with low cardiac output.
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